Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Bansky G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. Inflamm Bowel Dis 2010
22.12.2010
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey
22.12.2010
Inflamm Bowel Dis 2010
Vavricka Stephan R, Michetti Pierre, Straumann Alex, Seibold Frank, Scharl Michael, Sauter Bernhard, de Saussure Philippe, Rogler Gerhard, Manz Michael, Geyer Martin, Felley Christian, Binek Janek, Bansky Georg, Schoepfer Alain M, for the Swiss IBDnet
Weiter
